

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1644**



PATENT
Attorney Docket No. 219490
DHHS Reference No. E-221-1995/0-US-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Topalian et al.

Application No. 08/533,895

Filed: September 26, 1995

For: MHC CLASS II RESTRICTED
MELANOMA ANTIGENS AND
THEIR USE IN THERAPEUTIC
METHODS

Art Unit: 1644

Examiner: Vandervegt, F. P.

RECEIVED
OCT 17 2003
TECH CENTER 1600/2900

SUPPLEMENTAL AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicants wish to thank Examiner Vandervegt for the telephonic interview, which took place on September 9, 2003. In view of the interview, please enter the following amendments and consider the following remarks.

10/16/2003 MAHMED1 00000118 121216 08533895

02 FC:1253 950.00 DA

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this Response to Office Action and all accompanying documents are, on the date indicated below, being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Examiner , Art Unit , Facsimile Number .

Name (Print/Type)	Mirella Gallegos		
Signature		Date	October 9, 2003

10/16/2003 MAHMED1 00000118 121216 08533895

03 FC:1202 450.00 DA